非小细胞肺癌组织中lncRNA MNX1-AS1、miR-218-5p的表达及临床意义

doi:10.20047/j.issn1673-7210.2023.08.22

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (1068 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the expression and clinical significance of long non-coding RNA (LncRNA) MNX1-AS1 and microRNA (miR)-218-5p in non-small cell lung cancer (NSCLC) tissues. Methods A total of 120 NSCLC patients diagnosed and treated in Hubei Provincial Hospital of Traditional Chinese Medicine from January 2015 to January 2017 were selected. The expression of LncRNA MNX1-AS1 and miR-218-5p were detected by fluorescence quantitative PCR from NSCLC tissues and paracancer tissues. The correlation between LncRNA MNX1-AS1 and miR-218-5p in NSCLC tissues and its clinicopathologic features were analyzed. The mean of LncRNA MNX1-AS1 and miR-218-5p relative expression levels (2.321、1.213) were divided into high and low expression groups to analyze their effects on survival and prognosis of patients with NSCLC. Results The expression of LncRNA MNX1-AS1 and miR-218-5p in NSCLC tissues was higher than that in paracancer tissues (P＜0.05). LncRNA MNX1-AS1 was negatively correlated with miR-218-5p (r=-0.561, P＜0.01). The expression of LncRNA MNX1-AS1 and miR-218-5p in patients with different lymph node metastases and tumor stages were statistically significant (P＜0.05). The survival curve of LncRNA MNX1-AS1 high-expression group was lower than that of LncRNA MNX1-AS1 low-expression group, and the survival curve of miR-218-5p low-expression group was lower than that of miR-218-5p high-expression group (P＜0.05). Conclusion The expression of LncRNA MNX1-AS1 increased and miR-218-5p decreased in NSCLC tissues, both of which are associated with poor prognosis of patients and may serve as prognostic evaluation indicators.

Key words： Non-small cell lung cancer LncRNA MNX1-AS1 miR-218-5p Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Qiyuan1 LI Chengyin1 ZHU Jing1 ZOU Yinshui1 ZHAO Yaying1 GUO Guanghui2

Cite this article:

WANG Qiyuan1 LI Chengyin1 ZHU Jing1 ZOU Yinshui1 ZHAO Yaying1 GUO Guanghui2. Expression and clinical significance of lncRNA MNX1-AS1 and miR-218-5p in non-small cell lung cancer tissues[J]. 中国医药导报, 2023, 20(8): 99-102,110.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.08.22 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I8/99

[1] Bade BC，Dela Cruz CS. Lung Cancer 2020：Epidemiology，Etiology，and Prevention [J]. Clin Chest Med，2020，41（1）：1-24.
[2] Wang J，Zhu S，Meng N，et al. ncRNA-Encoded Peptides or Proteins and Cancer [J]. Mol Ther，2019，27（10）：1718- 1725.
[3] Liu X，Yang Q，Yan J，et al. LncRNA MNX1-AS1 promotes the progression of cervical cancer through activating MAPK pathway [J]. J Cell Biochem，2019，120（3）：4268-4277.
[4] Ma B，Ren G，Xu J，et al. LncRNA MNX1-AS1 Contributes to Laryngeal Squamous Cell Carcinoma Growth and Migration by Regulating mir-744-5p/bcl9/β-Catenin Axis [J]. Cell Transplant，2021，30（5）：9636-9642.
[5] Peng P，Chen T，Wang Q，et al. Decreased miR-218-5p Levels as a Serum Biomarker in Bone Metastasis of Prostate Cancer [J]. Oncol Res Treat，2019，42（4）：165-185.
[6] Li Y，Shi B，Dong F，et al. LncRNA KCNQ1OT1 facilitates the progression of bladder cancer by targeting MiR-218- 5p/HS3ST3B1 [J]. Cancer Gene Ther，2021，28（3/4）：212- 220.
[7] 任占良，张泳，任小朋，等.非小细胞肺癌手术单孔胸腔镜淋巴结清除术应用研究[J].中华肿瘤防治杂志，2021，28（5）：365-368.
[8] Hui Z，Men Y，Hu C，et al. Effect of Postoperative Radiotherapy for Patients With pⅢA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy：The Phase 3 PORT-C Randomized Clinical Trial [J]. JAMA Oncol，2021，7（8）：1178-1185.
[9] 夏雯洁，张雅婷，涂琳琳，等.长链非编码RNA作为自身免疫病生物标志物的研究进展[J].现代免疫学，2022，42（1）：64-71.
[10] 汪贝贝，张文波，蒋鹏程.长链非编码RNA参与调控细胞程序性死亡的研究进展[J].中国比较医学杂志，2022， 32（5）：147-154.
[11] Zhou B，Yang H，Yang C，et al. Translation of noncoding RNAs and cancer [J]. Cancer Lett，2021，497（28）：89- 99.
[12] Liu H，Han L，Liu Z，et al. Long noncoding RNA MNX1- AS1 contributes to lung cancer progression through the miR-527/BRF2 pathway [J]. J Cell Physiol，2019，234（8）：13843-13850.
[13] 张维，张珂，蒋力，等.lncRNA MNX1-AS1在结直肠癌中的临床意义及功能研究[J].标记免疫分析与临床，2020， 27（5）：833-838.
[14] Wu Q，Luo X，Liu J，et al. MYC-Activated LncRNA Promotes the Progression of Colorectal Cancer by Stabilizing YB1 [J]. Cancer Res，2021，81（10）：2636-2650.
[15] Liang D，Tian C，Zhang X. lncRNA MNX1-AS1 promotes prostate cancer progression through regulating miR-2113/ MDM2 axis [J]. Mol Med Rep，2022，26（1）：231-240.
[16] Li J，Li Q，Li D，et al. Long Non-Coding RNA MNX1-AS1 Promotes Progression of Triple Negative Breast Cancer by Enhancing Phosphorylation of Stat3 [J]. Front Oncol，2020，10（6）：1108-1117.
[17] Hu S，Li Z，Lutz H，et al. Dermal exosomes containing miR- 218-5p promote hair regeneration by regulating β-catenin signaling [J]. Sci Adv，2020，6（30）：1685-1692.
[18] Yang Y，Zhao F，Yuan Z，et al. Inhibition of miR-218-5p reduces myocardial ischemia-reperfusion injury in a Sprague-Dawley rat model by reducing oxidative stress and inflammation through MEF2C/NF-κB pathway [J]. Int Immunopharmacol，2021，101（Pt B）：1082-1099.
[19] 朱海龙，朱旭友.结直肠腺瘤中的miR-218-5p表达研究[J].中国当代医药，2021，28（35）：91-94.
[20] 杜正平，李海龙，刘春萍，等.miR-218-5p在胃癌细胞和胃癌组织中表达的临床意义及生物信息学分析[J]. 检验医学与临床，2020，17（7）：876-880.
[21] Wang J，Shu H，Xu C，et al. LncRNA DGCR5 promotes non- small cell lung cancer progression via sponging miR-218- 5p [J]. Eur Rev Med Pharmacol Sci，2019，23（22）：9947- 9954.
[22] Wang A，Dai H，Gong Y，et al. ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis [J]. J Exp Clin Cancer Res，2019，38（1）：347-353.
[23] Meng X，Zhang Y，Hu Y，et al. LncRNA CCAT1 sponges miR-218-5p to promote EMT，cellular migration and invasion of retinoblastoma by targeting MTF2 [J]. Cell Signal，2021，86（5）：1100-1112.
[24] Wang H，Zhan M，Xu S，et al. miR-218-5p restores sensitivity to gemcitabine through PRKCE/MDR1 axis in gallbladder cancer [J]. Cell Death Dis，2017，8（5）：2770- 2781.
[25] 曹军营，崔素娟，刘高峰，等.lncRNA MNX1-AS1通过调控miR-218-5p影响非小细胞肺癌细胞的增殖、凋亡及迁移[J].中南医学科学杂志，2022，50（3）：336- 340.